163 related articles for article (PubMed ID: 15325031)
1. Endothelial cell effects of cytotoxics: balance between desired and unwanted effects.
de Vos FY; Willemse PH; de Vries EG; Gietema JA
Cancer Treat Rev; 2004 Oct; 30(6):495-513. PubMed ID: 15325031
[TBL] [Abstract][Full Text] [Related]
2. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications.
Soultati A; Mountzios G; Avgerinou C; Papaxoinis G; Pectasides D; Dimopoulos MA; Papadimitriou C
Cancer Treat Rev; 2012 Aug; 38(5):473-83. PubMed ID: 21982720
[TBL] [Abstract][Full Text] [Related]
3. Taking down tumors: vascular disrupting agents entering clinical trials.
O'Hanlon LH
J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
[No Abstract] [Full Text] [Related]
4. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells.
Pasquier E; Honore S; Pourroy B; Jordan MA; Lehmann M; Briand C; Braguer D
Cancer Res; 2005 Mar; 65(6):2433-40. PubMed ID: 15781659
[TBL] [Abstract][Full Text] [Related]
5. Effects of lipoxin A(4) on CoCl(2)-induced angiogenesis and its possible mechanisms in human umbilical vein endothelial cells.
Liu S; Wu P; Ye D; Huang Y; Zhou X; Li Y; Cai L
Pharmacology; 2009; 84(1):17-23. PubMed ID: 19478549
[TBL] [Abstract][Full Text] [Related]
6. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
Bischof M; Abdollahi A; Gong P; Stoffregen C; Lipson KE; Debus JU; Weber KJ; Huber PE
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1220-32. PubMed ID: 15519795
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor actions of major component 3'-O-acetylhamaudol of Angelica japonica roots through dual actions, anti-angiogenesis and intestinal intraepithelial lymphocyte activation.
Kimura Y; Sumiyoshi M; Baba K
Cancer Lett; 2008 Jun; 265(1):84-97. PubMed ID: 18358599
[TBL] [Abstract][Full Text] [Related]
8. Vascular damaging agents.
Patterson DM; Rustin GJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
[TBL] [Abstract][Full Text] [Related]
9. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
Qiu H; Wang GM
Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis associated with angiogenesis inhibitors.
Elice F; Rodeghiero F; Falanga A; Rickles FR
Best Pract Res Clin Haematol; 2009 Mar; 22(1):115-28. PubMed ID: 19285278
[TBL] [Abstract][Full Text] [Related]
11. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies.
Hida K; Hida Y; Shindoh M
Cancer Sci; 2008 Mar; 99(3):459-66. PubMed ID: 18167133
[TBL] [Abstract][Full Text] [Related]
12. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
13. 2-Methoxyestradiol--a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents.
Sutherland TE; Anderson RL; Hughes RA; Altmann E; Schuliga M; Ziogas J; Stewart AG
Drug Discov Today; 2007 Jul; 12(13-14):577-84. PubMed ID: 17631253
[TBL] [Abstract][Full Text] [Related]
14. [Result of antineoplastic agents screening: 7th report].
Gan To Kagaku Ryoho; 1998 Mar; 25 Suppl 2():147-392. PubMed ID: 9551093
[No Abstract] [Full Text] [Related]
15. Vascular endothelium: target or victim of cytostatic therapy?
Romanov YA; Chervontseva AM; Savchenko VG; Smirnov VN
Can J Physiol Pharmacol; 2007; 85(3-4):396-403. PubMed ID: 17612648
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
17. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.
Zerp SF; Vink SR; Ruiter GA; Koolwijk P; Peters E; van der Luit AH; de Jong D; Budde M; Bartelink H; van Blitterswijk WJ; Verheij M
Anticancer Drugs; 2008 Jan; 19(1):65-75. PubMed ID: 18043131
[TBL] [Abstract][Full Text] [Related]
18. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
19. Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis.
Bahramsoltani M; Plendl J
APMIS; 2007 Jan; 115(1):30-46. PubMed ID: 17223849
[TBL] [Abstract][Full Text] [Related]
20. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies.
McDougall SR; Anderson AR; Chaplain MA
J Theor Biol; 2006 Aug; 241(3):564-89. PubMed ID: 16487543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
